46 results about "Corneal epithelial cell" patented technology

The invention provides a methacrylic anhydride modified sclera extracellular matrix repair material and a curing method thereof, and belongs to the technical field of medical repair materials. The methacrylic anhydride modified sclera extracellular matrix repair material provided by the invention is prepared from the following raw materials: a methacrylic anhydride modified sclera extracellular matrix, methacrylated gelatin, a photoinitiator and a solvent. The sclera extracellular matrix modified by methacrylic anhydride is adopted, methacrylic anhydride contains methacrylic acid, double bonds can be introduced, the sclera extracellular matrix has the photo-initiation polymerization capacity, and in-situ gelling can be carried out at sclera and cornea damage positions under the action of a photoinitiator; the sclera extracellular matrix has good biocompatibility and histocompatibility, so that sclera matrix cells and corneal epithelial cells are adhered and proliferated, and the sutureless repair is realized; the methacrylated gelatin can provide a photo-crosslinking gelatin network under the action of a photoinitiator, so that cell adhesion and proliferation can be promoted, and repair is realized.

This invention relates to the use of recombinant type III humanized collagen and compositions comprising thereof in the ocular field. The invention provides the use of recombinant type III humanized collagen in the preparation of products for the prevention and / or treatment of ocular inflammation, and compositions comprising recombinant type III humanized collagen, and the use of these compositions in the preparation of products for the prevention and / or treatment of ocular inflammation and / or dry eye. Recombinant type III humanized collagen and compositions comprising thereof can significantly promote the renewal and repair of corneal epithelial cells, while inhibiting the release of inflammatory mediators, strengthening the ocular tissue barrier, enhancing tear film stability, and relieving ocular inflammation and dry eye.

The invention belongs to the technical field of biomedicine, and relates to a novel application of 3-O-methyl chrysotoxin, in particular to an application of 3-O-methyl chrysotoxin in preparation of a medicine for treating xerophthalmia. The core of the 3-O-methyl chrysotoxin disclosed by the invention is that the 3-O-methyl chrysotoxin effectively relieves corneal epithelial cell injury induced by hyperosmosis and inhibits oxidative stress and proinflammatory factor release by activating an EGFR (Epidermal Growth Factor Receptor) signal channel. In-vitro and in-vivo experiments prove that the composition can remarkably enhance cell activity, reduce apoptosis and active oxygen accumulation and repair the steady state of a tear film. The compound is applied to preparation of xerophthalmia drugs and has important clinical value.

The present application belongs to the technical field of contact lenses, and provides a contact lens containing PDRN and a preparation method thereof. The contact lens is pretreated to obtain a plasma lens; the plasma lens is sequentially soaked in a first PDRN solution, a hyaluronic acid solution, a second PDRN solution and a taurine solution to obtain a semi-finished lens; and the semi-finished lens is crosslinked to obtain the contact lens containing PDRN. Through the design of a multi-layer structure, the present application realizes the synchronous and synergistic implantation of PDRN, hyaluronic acid and taurine in the contact lens. Among them, PDRN activates the A2A adenosine receptor signaling pathway, plays a core therapeutic role in promoting corneal epithelial cell proliferation, inhibiting the release of inflammatory factors and accelerating tissue repair; hyaluronic acid plays a role in lubricating and protecting the cornea; and taurine can scavenge active oxygen free radicals and reduce oxidative stress damage.

The application relates to the technical field of ophthalmic material preparation, and particularly discloses a kind of biopolymer membranes, a preparation method thereof and application in ophthalmic surgery.The biopolymer membrane comprises the following raw material components by weight: polyvinyl alcohol 5-10 parts;gelatin 3-6 parts;sodium lignosulfonate 10-20 parts;carboxymethyl cellulose 3-6 parts;natural extract 1-3 parts;water 200-300 parts.Studies have shown that the biopolymer membrane can promote the proliferation of human corneal epithelial cells;therefore, it has important application value when used in ophthalmic surgery for the treatment of ocular surface damage.

This invention discloses the application of low-concentration topical anesthetics in ophthalmic surgery, relating to the field of low-concentration topical anesthetic application technology, including the following specific application process: confirming the patient's basic surgical condition before administration; selecting anesthetic drugs and optimizing the administration concentration; performing administration according to the specific situation; real-time dynamic monitoring and adjustment of the administration dosage; gradually reducing the drug and transitioning to withdrawal. This invention improves drug safety and patient compliance while ensuring analgesic effects by optimizing anesthetic drug concentration and administration method. Furthermore, by using topical anesthetics at concentrations lower than conventional anesthetics for local administration after ophthalmic surgery, it can effectively relieve postoperative pain, discomfort, and foreign body sensation while significantly reducing toxic effects on corneal epithelial cells, reducing delayed corneal healing, dry eye, and corneal damage. It is effectively applicable to analgesia management after pterygium excision, refractive surgery, and other common ophthalmic surgeries, and has good clinical application value.

The invention discloses a small-molecule active aldehyde scavenger-albumin coupling medicine as well as a preparation method and application of the small-molecule active aldehyde scavenger-albumin coupling medicine. The coupling drug comprises a) the small molecule active aldehyde scavenger compound or the derivative thereof and b) albumin, and the albumin comprises at least one of human serum albumin, recombinant albumin, bovine serum albumin, ovalbumin and mouse serum albumin. The medicine is further prepared into an ophthalmic preparation, the retention time of the medicine in the cornea is prolonged, the in-vitro active aldehyde removal efficiency of the medicine is improved to 1.5 times of that of NS-2, expression (larger than or equal to 50%) of a human corneal epithelial cell inflammatory factor IL-6 is remarkably inhibited, and irritation to eyes is avoided. Through the synergistic effect of long-acting slow release of the albumin carrier and targeted removal of NS, the technical defects that a traditional xerophthalmia medicine is short in effect and single in mechanism are overcome, and a definite clinical transformation value is achieved.

The invention belongs to the technical field of medicine preparation, and provides an ophthalmic external preparation and a preparation method thereof. According to the ophthalmic external preparation, curcumin included by hydroxypropyl-beta-cyclodextrin loaded on exosome modified by polylysine is adopted as an effective component. The preparation can improve the drug concentration of cornea tissues and realize accurate delivery of ocular surfaces; meanwhile, the exosome and curcumin form a synergistic effect, so that the release of proinflammatory factors such as IL-1beta and TNF-alpha can be inhibited, the secretion of goblet cell mucoprotein and the proliferation of corneal epithelial cells can be promoted, and the tear film rupture time is prolonged; in addition, the preparation is excellent in biocompatibility, free of ocular surface stimulation reaction and high in safety.

The present invention belongs to the field of biotechnology, and specifically relates to a duck corneal epithelial cell suspension cell line, its construction method, and application. The present invention is the first to isolate and obtain adult corneal epithelial cells from ducks and successfully suspend and domesticate them. The cell line is named Duck Corneal Epithelial Suspension Cells (DCE-S) and was deposited in the China Center for Type Culture Collection at Wuhan University, Wuhan, China on June 28, 2024, with the deposit number CCTCC NO: C2024189. The cell line is easy to culture, grows rapidly, can be stably passaged, and has a high cell density of 6 to 8×10 6 cells / mL, exhibiting individually dispersed growth, plump morphology, uniform size, and high cell viability, making it suitable for serum-free suspension culture in bioreactors. This cell line can be used to culture, isolate, and detect avian viruses, prepare avian vaccines, and screen for drugs used to prevent or treat diseases caused by avian viral infections.

The invention provides a means for treating a disease involving damage of corneal epithelial cells. In particular, the invention provides a composition for use in treating a disease involving damage of corneal epithelial cells, as well as a use thereof. The composition includes (E)-2-(7-trifluoromethyl-chroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalene-1-yl)acetamide, a pharmaceutically acceptable salt thereof, or a solvate thereof.

The invention provides oxygen-enriched eye drops based on oxygen-containing lipidosome and application of the oxygen-enriched eye drops. The preparation method comprises the following steps: firstly, preparing blank liposome powder through a film dispersion-freeze drying technology, carrying out oxygenation treatment on the blank liposome powder to prepare oxygen-containing liposome, and then mixing the oxygen-containing liposome with sodium hyaluronate eye drops to obtain the oxygen-enriched eye drops. According to the oxygen-enriched eye drops, the permeability of oxygen in corneal tissues is improved, proliferation of corneal epithelial cells is remarkably promoted, and the apoptosis process of the corneal epithelial cells is delayed. The oxygen-enriched eye drops can promote repair after corneal epithelium injury.

The present invention discloses a preparation method and application of a metal ion coordination gel, wherein the gel material comprises: H-(RADA)4 and (RADA)4 gel stock solution, through histidine (His) and Cu 2+ The resulting complex solution, H-(RADA)4-Cu, is then mixed evenly with the (RADA)4 solution and added to a PBS buffer solution to form a stable gel. This gel exhibits excellent biocompatibility, promotes corneal epithelial cell repair, inhibits the growth of Staphylococcus aureus (S. aureus) and Escherichia coli (E. coli), and is effective in treating keratitis.

According to the application of the doxycycline and the compound composition of the doxycycline in preparation of the corneal injury repairing medicine, corneal collagenase is inhibited through the doxycycline, repairing of corneal epithelium is facilitated, and the oculentum preparation can act on cornea more enduringly, so that corneal repairing of alkali burn patients, dry eye patients and ocular surface injury patients is promoted, and the curative effect of the oculentum preparation is improved. According to the eye ointment, corneal epithelial cells can be effectively treated, regeneration and healing of the corneal epithelial cells are accelerated, hormones and non-steroidal anti-inflammatory components are added, ocular surface inflammatory response can be specifically inhibited, symptoms such as red and swollen eyes and pain can be relieved, the repairing effect of corneal epithelium can be enhanced, all the components are uniformly dispersed in the eye ointment by optimizing the preparation process, the stability of the eye ointment is guaranteed, and the eye ointment has good application prospects. The phenomena of layering, devitrification and the like are not easy to occur in the storage process, and stable and reliable product quality is ensured.

The invention provides a method for constructing a tissue engineered cornea based on human amniotic epithelial stem cells and application, and belongs to the technical field of biology. The method comprises the following steps: 1) culturing human amniotic epithelial stem cells in a corneal epithelial cell induced differentiation culture medium to obtain human corneal epithelial cell-like cells; culturing the human amniotic epithelial stem cells in a corneal stroma cell induced differentiation culture medium to obtain corneal stroma cells; and 2) respectively inoculating the human corneal epithelial cell-like cells and corneal stroma cells obtained in the step 1) on the surface and inside of an acellular corneal stroma scaffold, and co-culturing for 5 days to construct the tissue engineered cornea. According to the method, the two corneal cells derived from the human amniotic epithelial stem cells are simultaneously inoculated to the human decellularized corneal stroma for the first time, the tissue-engineered cornea is successfully constructed, in addition, the corneal cells obtained through differentiation can be inoculated to various types of biological materials such as hydrogel, and the tissue-engineered cornea is obtained. Wider application possibility is provided for developing various novel artificial cornea products.

The invention provides application of Mafb as a target spot in promotion of diabetic corneal epithelium injury repair, and belongs to the technical field of biological medicine. According to the application, the Mafb gene is taken as a treatment target, the repair speed of corneal epithelium injury can be obviously accelerated by over-expressing the Mafb gene in the cornea of a diabetic patient, and the expression levels of stem cell markers and cell proliferation markers in corneal epithelium tissues are obviously up-regulated. The invention also provides a recombinant adeno-associated virus AAV9-Mafb for overexpressing the Mafb gene, and the AAV9-Mafb can significantly recover the function of the corneal limbal stem cells of the diabetic mouse and promote the proliferation of corneal epithelial cells, thereby accelerating the repair of corneal epithelium injury of the diabetic mouse.

The invention relates to the field of biological medicines, in particular to application of an anoxic mesenchymal stem cell exosome in preparation of a medicine for promoting corneal epithelium injury healing. In-vivo and in-vitro experiments prove that the hypoxia mesenchymal stem cell exosome can remarkably restore inhibition on corneal epithelium injury healing under a hypertonic condition in vivo and in vitro, can remarkably promote proliferation and migration of human corneal epithelium cells in vitro, can promote corneal epithelium injury healing in vivo, has a good treatment effect on corneal epithelium injury, and can be used for treating corneal epithelium injury. Good application prospects are realized.

This invention relates to a small molecule compound composition and its applications, belonging to the field of biotechnology. The small molecule compound composition of this invention includes NU7441, GW9662, and D609, or their stereoisomers. This invention is the first to discover that this small molecule compound combination can effectively inhibit oxidative damage to corneal epithelial cells caused by hyperosmolarity and significantly improve the survival rate of corneal epithelial cells. In vivo animal experiments show that, compared with the control group, the experimental group of mice injected with scopolamine-induced dry eye model mice, given eye drops containing the small molecule compound combination, showed significantly reduced corneal defects and increased tear secretion. The small molecule compound combination can effectively prevent corneal epithelial damage, has high efficacy, and no obvious drug toxicity. This small molecule compound combination may become a potent and effective drug for the clinical treatment of dry eye in the future.

The present invention addresses the problem of providing a novel therapeutic agent that is effective against diseases involving stratified squamous epithelial cells such as dry eye syndrome. The present invention is an agent for promoting normal differentiation / maturation of stratified squamous epithelial cells, which comprises a secretion of mesenchymal stem cells. It is preferable that the secretions not include animal serum, that the mesenchymal stem cells be adipose-derived mesenchymal stem cells, umbilical cord-derived mesenchymal stem cells, or bone marrow-derived mesenchymal stem cells, and that the stratified squamous epithelial cells be at least one selected from the group consisting of corneal epithelial cells, conjunctival epithelial cells, epidermal keratinocytes, oral epithelial cells, epiglottic epithelial cells, esophageal epithelial cells, vaginal epithelial cells, vocal fold epithelial cells, nasal epithelial cells, and nasal vestibular epithelial cells.

The invention relates to a construction method of tissue engineering corneal epithelial cells. The construction method comprises the following steps: obtaining corneal limbus tissue blocks; digesting the tissue block, and separating to obtain epithelial cells of the tissue block; the method comprises the following steps: attaching epithelial cells to ultrathin amniotic membrane-umbilical cord derived mesenchymal stem cells, culturing in an SHEM culture medium, changing the SHEM culture medium once every two days, culturing for a period of time, and culturing the epithelial cells for a period of time by using a gas-liquid interface culture method to promote the multi-layer growth of the epithelial cells, thereby obtaining the tissue engineering corneal epithelial cells. Through a controllable preparation scheme, the amniotic membrane carrier with a certain thickness is obtained so as to increase the transparency of the amniotic membrane carrier, meanwhile, the matrix surface of the amniotic membrane carrier is inoculated with MSC, the healthy corneal limbus matrix microenvironment of a human body is simulated, damaged corneal limbus tissue / corneal epithelium is better repaired or regenerated, and the ocular surface microenvironment is improved. The produced ultrathin amnion combined mesenchymal stem cell carrier can obviously improve the effect of a tissue engineering corneal epithelium transplantation operation.

According to the ascorbyl palmitate prodrug micelle and the preparation method and application thereof, when the AP (at) PFPP polymer prodrug micelle is prepared, the micelle with the optimal size and particle size distribution can be formed when the molar ratio of FPBA to AP is 1: 2, and an in-vitro cell experiment shows that the AP (at) PFPP micelle can remove excessive ROS in cells and protect mitochondrial membrane potential; and human corneal epithelial cells (HECs) are protected from oxidative stress injury caused by hypertonic. Experimental results of a dry eye mouse model prove that the AP-PFPP micelle can effectively treat the dry eye, and the AP-PFPP prodrug micelle provides a new thought for the treatment of the dry eye.

The application provides a method for constructing a tissue-engineered cornea based on human amniotic epithelial stem cells and application thereof, and belongs to the technical field of biotechnology. The method comprises the following steps: 1) culturing human amniotic epithelial stem cells in a corneal epithelial cell induction and differentiation culture medium to obtain human corneal epithelial cell-like cells; culturing the human amniotic epithelial stem cells in a corneal stromal cell induction and differentiation culture medium to obtain corneal stromal cells; 2) inoculating the human corneal epithelial cell-like cells and the corneal stromal cells obtained in step 1) on the surface and inside of a decellularized corneal stromal scaffold respectively, and co-culturing for 5 days to construct a tissue-engineered cornea. The application successfully constructs a tissue-engineered cornea by inoculating two kinds of corneal cells derived from human amniotic epithelial stem cells on a human decellularized corneal stromal at the same time for the first time. In addition, the obtained corneal cells can be inoculated on various types of biomaterials such as hydrogels, thereby providing a wider application possibility for developing various types of artificial cornea products.

The invention discloses application of a lactoferrin ophthalmic preparation in prevention and treatment of myopia. The invention provides an application of lactoferrin in preparation of an ophthalmic preparation for preventing and / or treating myopia. An optical defocus myopia mouse model is constructed to simulate axial myopia of teenagers and children, it is verified in the mouse model that lactoferrin eye drops of the same dosage can more remarkably inhibit myopia progress and prevent myopia progress than intraperitoneal injection, and the concentration of sclera drugs of the lactoferrin eye drops of the same dosage is higher than that of intraperitoneal injection; the whole-body drug concentration is low, and the whole-body influence is small; the lactoferrin eye drops have low toxicity to human corneal epithelial cells and human embryonic eye sclera fibroblasts, are high in safety and have small influence on cell activity; therefore, the effectiveness and safety of the lactoferrin ophthalmic preparation are verified, a new scheme is provided for preventing and treating myopia, and the lactoferrin ophthalmic preparation has a good application prospect.

The invention relates to a swing type lamp capable of adjusting dynamic distribution of light in space, and belongs to the technical field of lighting decorative lighting. A transmission device is arranged, a decorative lighting assembly is connected with the output end of the transmission device and used for controlling the decorative lighting assembly to swing, and it needs to be explained that the light intensity released by the decorative lighting assembly is constant; due to the swinging of the decorative lighting assembly, the light intensity in the area is changed constantly, and the change can be captured by the cornea of the human eye and cannot be captured by the retina, so that the change of the light intensity cannot be perceived by the human eye, but the enzyme activity of the cornea epithelial cells can be remarkably improved, and the problem that the user is in a constant-light-intensity environment for a long time, and the user experience is poor is solved. And the enzymatic activity of the corneal epithelial cells of the user is obviously reduced.

The present invention relates to use of a recombinant type III humanized collagen and a composition comprising the same in an eye. Provided are use of a recombinant type III humanized collagen in the preparation of a product for preventing and / or treating eye inflammation, a composition comprising the recombinant type III humanized collagen, and use of the composition in the preparation of a product for preventing and / or treating eye inflammation and / or eye dryness. The recombinant type III humanized collagen and the composition comprising the same can significantly promote the renewal and repair of corneal epithelial cells, and can also inhibit the release of inflammatory mediators, enhancing the ocular tissue barrier, enhancing tear film stability, and alleviating eye inflammation and eye dryness.

The invention discloses a bioengineering corneal cell culture solution for repairing corneal ulcer and a preparation process of the bioengineering corneal cell culture solution. According to the invention, the addition of various growth factors not only promotes the proliferation and differentiation of corneal cells, but also enhances the signal transduction between cells, thereby accelerating the repair process of corneal ulcer. The epidermal growth factor and the basic fibroblast growth factor mainly promote cell proliferation and migration and provide a new cell source for an ulcer surface; the transforming growth factor-beta regulates the synthesis and remodeling of an extracellular matrix, and is helpful for recovering the normal structure of the cornea; and the corneal cell growth factor specifically promotes the growth of corneal epithelial cells. Through the multi-factor synergistic effect, the ulcer repairing speed is increased, the repairing quality is improved, scar formation is reduced, and a clearer and healthier vision recovery effect is brought to a patient.

The invention relates to the technical field of ophthalmic drugs, and particularly discloses application of polysulfonic acid mucopolysaccharide in preparation of drugs for treating ophthalmic diseases, and the ophthalmic diseases comprise xerophthalmia, corneal injury, retinal vein occlusion (RVO) or filtration bubble scarring after glaucoma filtration operation. Experiments prove that the polysulfonic mucopolysaccharide can prolong the tear film rupture time of a dry eye rabbit model, reduce the cornea fluorescein staining score, improve the optimal corrected vision of acute retinal vein occlusion patients, reduce the macular center thickness and inhibit the expression level of lipopolysaccharide-induced human corneal epithelial cell IL-6 and TNF-alpha inflammatory factors, and can be used for treating acute retinal vein occlusion. The migration and proliferation speed of the human corneal epithelial cells is improved.

The invention discloses mink gallbladder eye drops and preparation thereof. The eye drops comprise a composition for protecting cornea, and the preparation method of the eye drops comprises the following steps: adding a mink bile total cholic acid extract and carnosine powder into an ethanol water solution, heating for dissolving, filtering, and concentrating and drying the obtained filtrate to obtain the eye drops. According to the eye drops, corneal epithelial cell injury is repaired, corneal epithelial cell hyaluronic acid secretion is promoted, and therefore eye dryness and fatigue can be relieved, and cornea can be effectively protected.

The invention discloses application of a traditional Chinese medicine composition in preparation of a medicine for improving xerophthalmia, and belongs to the technical field of medicine. Pharmacological experiments prove that the traditional Chinese medicine composition processed by taking radix astragali preparata or radix astragali, fructus lycii, herba ecliptae, wine-processed fructus ligustri lucidi, radix polygalae preparata, rhizoma chuanxiong, radix panacis quinquefolii, rhizoma acori graminei and herba menthae as raw materials can relieve inflammation infiltration appearing in corneal stroma, increase the thickness of a corneal epithelial cell layer and improve the corneal growth rate. Tear secretion and corneal fluorescein sodium staining scores of dry eye mice are improved, corneal epithelial cell apoptosis and corneal inflammation are inhibited, and then the dry eye syndrome is improved. Therefore, the traditional Chinese medicine composition has a good application prospect in the aspect of clinical medicine for treating xerophthalmia.

The first object of the invention is a fibrin patch containing corneal limbal epithelial cells, characterized in that it contains a protein substrate, which is dried and rehydrated fibrin, a density of corneal limbal epithelial cells on the protein substrate is from 5,000 cells / cm2 to 70,000 cells / cm2, and the protein substrate does not contain a nutrient layer. The invention discloses also the method of the manufacturing of the patch.

The application discloses a small-molecule active aldehyde scavenger-albumin coupled drug, a preparation method and application thereof, the coupled drug comprising a) the small-molecule active aldehyde scavenger compound or its derivative, and b) albumin, the albumin comprising at least one of human serum albumin, recombinant albumin, bovine serum albumin, ovalbumin and mouse serum albumin. The drug is further prepared into an ophthalmic preparation, the retention time of the drug in the cornea is improved, the efficiency of in-vitro scavenging active aldehyde is improved to 1.5 times of NS-2, the expression of inflammatory factor IL-6 of human corneal epithelial cells is significantly inhibited (greater than or equal to 50%), and the drug has no irritation to the eye. Through the long-acting sustained release of the albumin carrier and the synergistic effect of the targeted scavenging of NS, the technical defects of traditional dry eye drugs, such as short-acting and single mechanism, are overcome, and the drug has clear clinical transformation value.